Works matching IS 13520504 AND DT 2020 AND VI 27 AND IP 5
Results: 14
Deep sequence analysis of NS5A resistance‐associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 552, doi. 10.1111/jvh.13256
- By:
- Publication type:
- Article
Re‐treatment for severe hepatitis flare in HBeAg‐negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 544, doi. 10.1111/jvh.13253
- By:
- Publication type:
- Article
RNA testing for the diagnosis of acute hepatitis A during the 2017 outbreak in France.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 540, doi. 10.1111/jvh.13255
- By:
- Publication type:
- Article
Enhancing the hepatitis B care cascade in Australia: A cost‐effectiveness model.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 526, doi. 10.1111/jvh.13252
- By:
- Publication type:
- Article
Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct‐acting antiviral therapy including first‐ and second‐generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 548, doi. 10.1111/jvh.13254
- By:
- Publication type:
- Article
Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 514, doi. 10.1111/jvh.13263
- By:
- Publication type:
- Article
Real‐world experience of elbasvir/grazoprevir in Taiwan: This study was focused on liver and renal adverse effects.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 505, doi. 10.1111/jvh.13262
- By:
- Publication type:
- Article
Long‐term safety and efficacy results in hepatitis C virus genotype 1‒infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ‐I and TOPAZ‐II trials.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 497, doi. 10.1111/jvh.13261
- By:
- Publication type:
- Article
Enablers and barriers for the provision of community‐based HCV treatment: A case study of a real‐world practice.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 484, doi. 10.1111/jvh.13259
- By:
- Publication type:
- Article
Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 476, doi. 10.1111/jvh.13251
- By:
- Publication type:
- Article
Prevalence and impact of hepatitis B virus infection in ovarian cancer patients in an endemic area—A retrospective cohort study.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 520, doi. 10.1111/jvh.13250
- By:
- Publication type:
- Article
Effectiveness of single‐dose administration of inactivated hepatitis A virus vaccination in the Republic of Korea armed forces, 2013‐2016.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 537, doi. 10.1111/jvh.13249
- By:
- Publication type:
- Article
Asian consensus recommendations on optimizing the diagnosis and initiation of treatment of hepatitis B virus infection in resource‐limited settings.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 466, doi. 10.1111/jvh.13244
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Journal of Viral Hepatitis, 2020, v. 27, n. 5, p. 463, doi. 10.1111/jvh.13138
- Publication type:
- Article